Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Vladimir I. Kovalev has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • A. S. Dashkova

    Pushchino Scientific Center for Biological Research of the Russian Academy of Sciences

    1 shared publication
  • A. V. Chaplygina

    Pushchino Scientific Center for Biological Research of the Russian Academy of Sciences

    1 shared publication
  • Alesya V. Soboleva

    Center for Precision Genetic Technologies for Medicine, Engelhardt Institute of Molecular Biology of the Russian Academy of Sciences, 119991 Moscow, Russia

    1 shared publication
  • Alina Chaplygina

    Institute of Cell Biophysics of RAS, 142290, Pushchino, Moscow Region, Russian Federation

    1 shared publication
  • Alina V. Chaplygina

    Institute of Cell Biophysics, Russian Academy of Sciences, Pushchino, Russia

    1 shared publication
  • Alla S. Dashkova

    Institute of Cell Biophysics, Russian Academy of Sciences, Pushchino, Russia

    1 shared publication

Latest Publications

  • Open Access

    RNA Interference and Its Key Targets for Spinal Cord Injury Therapy: What Is Known So Far?

    by Daria Chudakova, Vladimir Kovalev, Matthew Shkap, Elizaveta Sigal, Arthur Biktimirov, Alesya Soboleva, Vladimir Baklaushev

    Spinal cord injury (SCI) is a neurological condition often resulting in permanent motor and sensory deficits, for which effective treatments remain limited. RNA interference (RNAi) is a post-transcriptional mechanism of the downregulation of gene expression mediated by small interfering RNAs. RNAi has demonstrated therapeutic efficacy in various neurological disorders, positioning it as a promising yet underexplored therapeutic strategy for SCI. Here, we provide a focused overview of the key pathological processes in SCI, including primary mechanical injury and secondary cascades such as inflammation, mitochondrial dysfunction, excitotoxicity, oxidative stress, multiple forms of cell death, and others. The potential of RNAi to selectively silence genes implicated in these pathological processes, thereby enhancing neuroprotection and functional recovery, is highlighted. We point out that not only protein-coding genes, but non-coding RNAs (ncRNAs) are suitable targets for RNAi. Novel RNAi tools such as CRISPR-Cas13 might revolutionize the field and offer new opportunities for SCI therapy. However, despite all these promising findings, relevant translational studies of RNAi remain scarce. Challenges related to delivery methods, long-term efficacy, and cell-specific targeting must be addressed. Importantly, combining RNAi with other strategies such as cell- or biomaterial-based therapies may enhance therapeutic outcomes. Future investigations should prioritize systematic comparisons of RNAi targets and delivery systems, ideally at single-cell resolution and in different SCI models, to identify the most relevant molecular pathways for clinical translation. Overall, RNAi represents a compelling but still underdeveloped approach for SCI therapy, requiring continued refinement to reach clinical application.


  • Unique Properties of Synaptosomes and Prospects for Their Use for the Treatment of Neurodegenerative Diseases (Review)

    by A. S. Dashkova, V. I. Kovalev, A. V. Chaplygina, D. Yu. Zhdanova, N. V. Bobkova

    Alzheimer’s disease (AD) is a severe neurodegenerative disease that affects millions of people around the world. The increasing prevalence of AD correlates with increasing life expectancy and aging populations in developed countries. Since AD is a multifactorial disease and includes various pathological processes, such as: synaptic dysfunction, neuroinflammation, oxidative stress, protein misfolding, etc., an integrated approach aimed simultaneously at several targets may be effective and slow down the progression of the disease. Cell therapy and its further development in the form of transplantation of cellular vesicles and especially mitochondria are a very promising approach for the treatment of neurodegeneration. The use of synaptosomes, due to the uniqueness of their content, may become a new stage in the development of complex therapy for neurodegenerative diseases and AD in particular. This review discusses the preparation and composition of synaptosomes, as well as the possibilities and advantages of their use as transporters for the delivery of synaptic mitochondria and other biologically active substances to the brain.

  • Unique Properties of Synaptosomes and Prospects for Their Use for the Treatment of Alzheimer’s Disease

    by Alla S. Dashkova, Vladimir I. Kovalev, Alina V. Chaplygina, Daria Yu. Zhdanova, Natalia V. Bobkova

    Alzheimer’s disease (AD) is a severe neurodegenerative condition affecting millions worldwide. Prevalence of AD correlates with increased life expectancy and aging population in the developed countries. Considering that AD is a multifactorial disease involving various pathological processes such as synaptic dysfunction, neuroinflammation, oxidative stress, and improper protein folding, a comprehensive approach targeting multiple pathways may prove effective in slowing the disease progression. Cellular therapy and its further development in the form of cell vesicle and particularly mitochondrial transplantation represent promising approaches for treating neurodegeneration. The use of synaptosomes, due to uniqueness of their contents, could mark a new stage in the development of comprehensive therapies for neurodegenerative diseases, particularly AD. Synaptosomes contain unique memory mitochondria, which differ not only in size but also in functionality compared to the mitochondria in the neuronal soma. These synaptosomal mitochondria actively participate in cellular communication and signal transmission within synapses. Synaptosomes also contain other elements such as their own protein synthesis machinery, synaptic vesicles with neurotransmitters, synaptic adhesion molecules, and microRNAs – all crucial for synaptic transmission and, consequently, cognitive processes. Complex molecular ensemble ensures maintenance of the synaptic autonomy of mitochondria. Additionally, synaptosomes, with their affinity for neurons, can serve as an optimal platform for targeted drug delivery to nerve cells. This review discusses unique composition of synaptosomes, their capabilities and advantages, as well as limitations of their suggested use as therapeutic agents for treating neurodegenerative pathologies, particularly AD.


  • Open Access

    Germinal proto-mitochondria from rat liver

    by Nikolai Vekshin, Vladimir Kovalev, Alina Chaplygina

  • Tyndall’s hypochromism in suspensions

    by N. L. Vekshin, M. S. Frolova, V. I. Kovalev, E. A. Begunova

    Passage of light through a suspension is accompanied by a competition of processes of absorption and scattering for each individual particle. As a result, a hypochromism phenomenon (a decrease in the extinction coefficient) takes place. The hypochromism value increases with the growth of a particle sizes or its refractive index. Since Tyndall’s light scattering in a suspension where the size of every particle is considerably larger than the wavelength weakly depends on the wavelength, the absorption (or excitation) spectrum is almost uniformly attenuated. A simple method for determination of the true extinction coefficients of the absorption and excitation spectra of diluted suspensions which have no multiple light scattering is proposed. Experimental data on the spectra of hemoglobin in erythrocytes, actinomycin in DNA, and flavines in mitochondria are discussed.